Reports
Sale
Global Cancer Tumor Profiling Market Size, Share, Report: By Product Type: Instruments, Consumables; By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancer; By Biomarker Type: Genomic Biomarker, Others; By Technology; By Application; Regional Analysis; Supplier Landscape; 2024-2032
Global Cancer Tumor Profiling Market Size
The global cancer tumor profiling market was valued at USD 11 billion in 2023 driven by increase in cancer cases, technological advancements in profiling technologies across the globe. The market is expected to grow at a CAGR of 11.70% during the forecast period 2024-2032 and attain a market value of USD 29.78 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Cancer Tumor Profiling Market Outlook
- Cancer is one of the leading causes of death in the worldwide. Globally, there were 9.7 million cancer-related deaths and about 20 million new cases in 2022. It is anticipated that by 2040, there would be 15.3 million cancer-related deaths and 29.9 million new instances of cancer annually.
- The primary drivers of the market include the rising incidence of cancer and the growing need for cancer tumor profiling in routine diagnostics, therapeutic decision-making, and the creation of personalized treatment plans and medicines.
- In 2024, North America is expected to dominate the market due to the high percentage of cancer cases, large investments in research and development.
Global Cancer Tumor Profiling Market Overview
Tumor profiling constitutes the pinnacle of efforts, where it aims to classify neoplasms into subgroups that give information about how cancer has evolved, how it can be better treated, and how should direct drug design strategies to treat them.
Tumor profiling is testing that looks at unique DNA changes in a patient’s tumor, and in recent years, significant advancements have been made in this field of cancer care. It is the technology oncologists use to determine if the pathways of a patient’s tumor match up with available targeted treatments. The tumor profiling process starts with obtaining a sample of tumor tissue. The tissue is usually collected through a core biopsy, but it can also be taken during surgery. Once the tissue sample is obtained, tumor DNA is extracted from the tumor cells, purified, and then sent to a lab. The DNA is tested, or sequenced, to look for gene mutations that could make the tumor responsive to certain treatments.
Global Cancer Tumor Profiling Market Growth Drivers
Rising Prevalence of Cancer
The worldwide cancer burden is increasing because of aging populations, lifestyle changes, and environmental causes. This increase in cancer incidence increases the requirement for sophisticated diagnostic and therapeutic options, such as tumor profiling.
The World Health Organization (WHO) estimates that 1 in 5 people will get cancer at some point in their lives, and around 1 in 9 men and 1 in 12 women will pass away from the illness. Furthermore, it is anticipated that there would be more than 35 million new cases of cancer in 2050, indicating a 77% rise from the projected 20 million cases in 2022. With approximately 1 in 6 deaths worldwide, cancer ranks as the second most common cause of death worldwide. Most cancer cases in the WHO's Eastern Mediterranean Region are discovered later in life when therapies are less successful and patient outcomes are worse. Based on estimates, the region is expected to have the largest increase in cancer burden among the six WHO regions by 2030.
Development in Genomic Technologies
Advances in next-generation sequencing (NGS) and other genomic analytic tools have greatly improved the capacity to sequence and study cancer genomes. These tools enable the full profiling of genetic mutations, copy number changes, and other molecular changes in malignancies.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Cancer Tumor Profiling Market Trends
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
| Key Trends | Impact |
| Increasing Emphasis on Biomarker Discovery and Validation | One of the major market trends include focus on utilizing biomarkers to get a detailed understanding of cancer molecular features, enabling targeted medicine selection to address genetic defects and improve treatment outcomes. Biomarkers are important in tumor profiling because it indicates early detection of cancer, diagnosis, prognosis, therapy response, cancer recurrence, and there is a rising emphasis on developing and verifying biomarkers for therapeutic decision making. It can differentiate cancer subtypes, provide prognosis information, aid in early identification, differential diagnosis, and monitoring of disease development, facilitating effective clinical decision-making. |
| Rise of Personalized Medicine | Personalized medicine is being utilized to assist in selecting the best course of therapy and diagnostics for some malignancies. Precision medicine may be used in healthcare to help patients identify individuals who may be more susceptible to cancer, lower their risk, detect certain malignancies early, accurately diagnose a specific type of cancer, choose the best cancer treatment options, and evaluate the effectiveness of each treatment. |
| Expansion of Next-Generation Sequencing (NGS) | The investigation of cancer genomes may be done objectively credits to next-generation sequencing (NGS) methods. NGS has made it possible to quickly identify thousands of genes linked to cancer from modest amounts of DNA. It is now affordably available in academic cancer centers and commercial testing facilities thanks to recent advancements in timeliness and affordability. |
| Patient-Centric Care and Awareness | Patients and healthcare professionals are becoming aware of the benefits of customized treatment and testing for cancer. They are becoming more knowledgeable and proactive in their search for tumor profiling services, which can provide tailored therapy alternatives and better therapeutic outcomes. |
Global Cancer Tumor Profiling Market Segmentation
Market Breakup by Product Type
- Instruments
- Consumables
- Kits
- Reagents
- Others
Market Breakup by Cancer Type
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Melanoma Cancer
- Other Cancer
Market Breakup by Biomarker Type
- Genomic Biomarker
- Protein Biomarker
Market Breakup by Technology
- Immunoassays
- Next-Generation Sequencing
- Polymerase Chain Reaction
- Mass Spectrometry
- Others
Market Breakup by Application
- Clinical
- Research
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Cancer Tumor Profiling Market Share
Market Share Based on Biomarker Types to Witness Growth in the Forecast Period
The market segmentation based on biomarker type is segmented into genomic biomarkers and protein biomarkers. Biomarkers are molecular indicators of a biological status, and as biochemical species can be assayed to determine the presence of cancer and therapeutic interventions. Genomic biomarkers examine genetic alterations, whereas protein biomarkers examine protein expression levels. The first biomarker to be used in diagnosis of cancer was protein biomarkers. The biomarker material produced by cancer cells can lead to their own identification, which then opens the door for their non-invasive detection in bodily fluids and tissues to identify tumor presence or tumor load.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Cancer Tumor Profiling Market Analysis by Region
Based on region, the market report covers North America, Europe, Asia Pacific, Latin America along with the Middle East and Africa. North America is poised to hold a significant market share in the forecast period, driven by an increasing percentage of cancer cases, large investments in research and development in the region. Furthermore, North America has a strong network of academic and research institutions, pharmaceutical and biotechnology companies, and other businesses that work together to promote innovation in cancer tumor profiling technologies.
The cancer tumor profiling market value in Europe is expanding rapidly, due to developments in targeted therapy and personalized medicine. This market includes the products and services that are meant to help with therapy selection by providing molecular tumor characterization.
The Asia Pacific market is experiencing rapid growth which is driven by several key factors which include the increase in incidence of cancer, personalized medicine, advancement in technology. For shaping the market dynamics, countries like China, Japan, India, and South Korea will play a vital role in the forecast period.
Leading Players in the Global Cancer Tumor Profiling Market
The key features of the market report include patent analysis as well as strategic initiatives including recent partnerships and collaborations by the leading players. The major companies in the market are as follows:
Illumina Inc.
Illumina, Inc, an American biotechnology business has its headquarters in San Diego, California. Established in 1998, Illumina is a company that designs, produces, and sells integrated technologies for the study of biological function and genetic diversity. Illumina, a pioneer in array-based technologies and genome sequencing, offers solutions for clinical and research settings, including thorough cancer tumor profiling.
NeoGenomics Laboratories
NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo has its headquarters in Fort Myers, FL. It operates a nationwide network of testing facilities, including labs in Florida. It is a high-complexity clinical laboratory with CLIA certification, pharmaceutical services provider, and information services provider with a focus on cancer genetics diagnostic testing. Among the testing services offered by the company are molecular genetics, immunohistochemistry, flow cytometry, cytogenetics, and fluorescence in situ hybridization (FISH).
Qiagen N.V.
QIAGEN N.V. is a German-founded international company that offers assay and sample technologies for molecular diagnostics, including QIAseq and QIAcuity technology for tumor profiling. The QIAGEN group’s global corporate headquarters are in Venlo, the Netherlands. The main operative headquarters are located in Hilden, Germany.
Caris Life Sciences
In 2008, Caris Life Sciences was established with the straightforward but effective goal of assisting in the improvement of as many people's lives as possible. To support individualized cancer treatment plans, it offers molecular profiling services, such as thorough tumor profiling and molecular intelligence solutions.
Guardant Health
Guardant Health is an American biotechnology company based in Palo Alto, California. It specializes in non-invasive liquid biopsy procedures that examines blood samples for circulating tumor DNA (ctDNA), which offers information regarding tumor mutation and treatment response.
Other players in the market include Abbott Laboratories, Becton Dickinson and Company, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Hologic, Inc., HTG Molecular Diagnostics Inc., Laboratory Corporation of America Holdings, Siemens AG, Sysmex Corporation and GenScript.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Cancer Type |
|
| Breakup by Biomarker Type |
|
| Breakup by Technology |
|
| Breakup by Application |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Questions Answered in the Global Cancer Tumor Profiling Market Report
- What was the global cancer tumor profiling market value in 2023?
- What is the global cancer tumor profiling market forecast outlook for 2024-2032?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on biomarker type?
- What is the market breakup based on application?
- Who are the major end users in the market?
- What are the major factors aiding the global cancer tumor profiling market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major trends influencing the market?
- What are the major drivers, opportunities, and restraints in the market?
- Which regional market is expected to dominate the market share in the forecast period?
- Which country is likely to experience elevated growth during the forecast period?
- Which application area is expected to have a high market value in the coming years?
- How does the prevalence and incidence of cancer affect the market landscape?
- Which end user will contribute significantly to the market growth?
- Who are the key players involved in the cancer tumor profiling market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Cancer Tumor Profiling Market Overview
3.1 Global Cancer Tumor Profiling Market Historical Value (2017-2023)
3.2 Global Cancer Tumor Profiling Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Global Cancer Tumor Profiling Market Landscape*
5.1 Global Cancer Tumor Profiling Health: Developers Landscape
5.1.1 Analysis by Year of Establishment
5.1.2 Analysis by Company Size
5.1.3 Analysis by Region
5.2 Global Cancer Tumor Profiling Health: Product Landscape
5.2.1 Analysis by Product Type
5.2.2 Analysis by Cancer Type
5.2.3 Analysis by Biomarker Type
6 Global Cancer Tumor Profiling Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
6.2.1 Strengths
6.2.2 Weaknesses
6.2.3 Opportunities
6.2.4 Threats
6.3 PESTEL Analysis
6.3.1 Political
6.3.2 Economic
6.3.3 Social
6.3.4 Technological
6.3.5 Legal
6.3.6 Environment
6.4 Porter’s Five Forces Model
6.4.1 Bargaining Power of Suppliers
6.4.2 Bargaining Power of Buyers
6.4.3 Threat of New Entrants
6.4.4 Threat of Substitutes
6.4.5 Degree of Rivalry
6.5 Key Demand Indicators
6.6 Key Price Indicators
6.7 Industry Events, Initiatives, and Trends
6.8 Value Chain Analysis
7 Global Cancer Tumor Profiling Market Segmentation (2017-2032)
7.1 Global Cancer Tumor Profiling Market (2017-2032) by Product Type
7.1.1 Market Overview
7.1.2 Instruments
7.1.3 Consumables
7.1.3.1 Kits
7.1.3.2 Reagents
7.1.3.3 Others
7.2 Global Cancer Tumor Profiling Market (2017-2032) by Cancer Type
7.2.1 Market Overview
7.2.2 Breast Cancer
7.2.3 Lung Cancer
7.2.4 Colorectal Cancer
7.2.5 Prostate Cancer
7.2.6 Melanoma Cancer
7.2.7 Other Cancer
7.3 Global Cancer Tumor Profiling Market (2017-2032) by Biomarker Type
7.3.1 Market Overview
7.3.2 Genomic Biomarker
7.3.3 Protein Biomarker
7.4 Global Cancer Tumor Profiling Market (2017-2032) by Technology
7.4.1 Market Overview
7.4.2 Immunoassays
7.4.3 Next-Generation Sequencing
7.4.4 Polymerase Chain Reaction
7.4.5 Mass Spectrometry
7.4.6 Others
7.5 Global Cancer Tumor Profiling Market (2017-2032) by Application
7.5.1 Market Overview
7.5.2 Clinical
7.5.3 Research
7.6 Global Cancer Tumor Profiling Market (2017-2032) by Region
7.6.1 Market Overview
7.6.2 North America
7.6.3 Europe
7.6.4 Asia Pacific
7.6.5 Latin America
7.6.6 Middle East and Africa
8 North America Cancer Tumor Profiling Market (2017-2032)
8.1 North America Cancer Tumor Profiling Market (2017-2032) by Product Type
8.1.1 Market Overview
8.1.2 Instruments
8.1.3 Consumables
8.1.3.1 Kits
8.1.3.2 Reagents
8.1.3.3 Others
8.2 North America Cancer Tumor Profiling Market (2017-2032) by Cancer Type
8.2.1 Market Overview
8.2.2 Breast Cancer
8.2.3 Lung Cancer
8.2.4 Colorectal Cancer
8.2.5 Prostate Cancer
8.2.6 Melanoma Cancer
8.2.7 Other Cancer
8.3 North America Cancer Tumor Profiling Market (2017-2032) by Biomarker Type
8.3.1 Market Overview
8.3.2 Genomic Biomarker
8.3.3 Protein Biomarker
8.4 North America Cancer Tumor Profiling Market (2017-2032) by Technology
8.4.1 Market Overview
8.4.2 Immunoassays
8.4.3 Next-Generation Sequencing
8.4.4 Polymerase Chain Reaction
8.4.5 Mass Spectrometry
8.4.6 Others
8.5 North America Cancer Tumor Profiling Market (2017-2032) by Application
8.5.1 Market Overview
8.5.2 Clinical
8.5.3 Research
8.6 North America Cancer Tumor Profiling Market (2017-2032) by Country
8.6.1 United States of America
8.6.2 Canada
9 Europe Cancer Tumor Profiling Market (2017-2032)
9.1 Europe Cancer Tumor Profiling Market (2017-2032) by Product Type
9.1.1 Market Overview
9.1.2 Instruments
9.1.3 Consumables
9.1.3.1 Kits
9.1.3.2 Reagents
9.1.3.3 Others
9.2 Europe Cancer Tumor Profiling Market (2017-2032) by Cancer Type
9.2.1 Market Overview
9.2.2 Breast Cancer
9.2.3 Lung Cancer
9.2.4 Colorectal Cancer
9.2.5 Prostate Cancer
9.2.6 Melanoma Cancer
9.2.7 Other Cancer
9.3 Europe Cancer Tumor Profiling Market (2017-2032) by Biomarker Type
9.3.1 Market Overview
9.3.2 Genomic Biomarker
9.3.3 Protein Biomarker
9.4 Europe Cancer Tumor Profiling Market (2017-2032) by Technology
9.4.1 Market Overview
9.4.2 Immunoassays
9.4.3 Next-Generation Sequencing
9.4.4 Polymerase Chain Reaction
9.4.5 Mass Spectrometry
9.4.6 Others
9.5 Europe Cancer Tumor Profiling Market (2017-2032) by Application
9.5.1 Market Overview
9.5.2 Clinical
9.5.3 Research
9.6 Europe Cancer Tumor Profiling Market (2017-2032) by Country
9.6.1 United Kingdom
9.6.2 Germany
9.6.3 France
9.6.4 Italy
9.6.5 Others
10 Asia Pacific Cancer Tumor Profiling Market (2017-2032)
10.1 Asia Pacific Cancer Tumor Profiling Market (2017-2032) by Product Type
10.1.1 Market Overview
10.1.2 Instruments
10.1.3 Consumables
10.1.3.1 Kits
10.1.3.2 Reagents
10.1.3.3 Others
10.2 Asia Pacific Cancer Tumor Profiling Market (2017-2032) by Cancer Type
10.2.1 Market Overview
10.2.2 Breast Cancer
10.2.3 Lung Cancer
10.2.4 Colorectal Cancer
10.2.5 Prostate Cancer
10.2.6 Melanoma Cancer
10.2.7 Other Cancer
10.3 Asia Pacific Cancer Tumor Profiling Market (2017-2032) by Biomarker Type
10.3.1 Market Overview
10.3.2 Genomic Biomarker
10.3.3 Protein Biomarker
10.4 Asia Pacific Cancer Tumor Profiling Market (2017-2032) by Technology
10.4.1 Market Overview
10.4.2 Immunoassays
10.4.3 Next-Generation Sequencing
10.4.4 Polymerase Chain Reaction
10.4.5 Mass Spectrometry
10.4.6 Others
10.5 Asia Pacific Cancer Tumor Profiling Market (2017-2032) by Application
10.5.1 Market Overview
10.5.2 Clinical
10.5.3 Research
10.6 Asia Pacific Cancer Tumor Profiling Market (2017-2032) by Country
10.6.1 China
10.6.2 Japan
10.6.3 India
10.6.4 ASEAN
10.6.5 Australia
10.6.6 Others
11 Latin America Cancer Tumor Profiling Market (2017-2032)
11.1 Latin America Cancer Tumor Profiling Market (2017-2032) by Product Type
11.1.1 Market Overview
11.1.2 Instruments
11.1.3 Consumables
11.1.3.1 Kits
11.1.3.2 Reagents
11.1.3.3 Others
11.2 Latin America Cancer Tumor Profiling Market (2017-2032) by Cancer Type
11.2.1 Market Overview
11.2.2 Breast Cancer
11.2.3 Lung Cancer
11.2.4 Colorectal Cancer
11.2.5 Prostate Cancer
11.2.6 Melanoma Cancer
11.2.7 Other Cancer
11.3 Latin America Cancer Tumor Profiling Market (2017-2032) by Biomarker Type
11.3.1 Market Overview
11.3.2 Genomic Biomarker
11.3.3 Protein Biomarker
11.4 Latin America Cancer Tumor Profiling Market (2017-2032) by Technology
11.4.1 Market Overview
11.4.2 Immunoassays
11.4.3 Next-Generation Sequencing
11.4.4 Polymerase Chain Reaction
11.4.5 Mass Spectrometry
11.4.6 Others
11.5 Latin America Cancer Tumor Profiling Market (2017-2032) by Application
11.5.1 Market Overview
11.5.2 Clinical
11.5.3 Research
11.6 Latin America Cancer Tumor Profiling Market (2017-2032) by Country
11.6.1 Brazil
11.6.2 Argentina
11.6.3 Mexico
11.6.4 Others
12 Middle East and Africa Cancer Tumor Profiling Market (2017-2032)
12.1 Middle East and Africa Cancer Tumor Profiling Market (2017-2032) by Product Type
12.1.1 Market Overview
12.1.2 Instruments
12.1.3 Consumables
12.1.3.1 Kits
12.1.3.2 Reagents
12.1.3.3 Others
12.2 Middle East and Africa Cancer Tumor Profiling Market (2017-2032) by Cancer Type
12.2.1 Market Overview
12.2.2 Breast Cancer
12.2.3 Lung Cancer
12.2.4 Colorectal Cancer
12.2.5 Prostate Cancer
12.2.6 Melanoma Cancer
12.2.7 Other Cancer
12.3 Middle East and Africa Cancer Tumor Profiling Market (2017-2032) by Biomarker Type
12.3.1 Market Overview
12.3.2 Genomic Biomarker
12.3.3 Protein Biomarker
12.4 Middle East and Africa Cancer Tumor Profiling Market (2017-2032) by Technology
12.4.1 Market Overview
12.4.2 Immunoassays
12.4.3 Next-Generation Sequencing
12.4.4 Polymerase Chain Reaction
12.4.5 Mass Spectrometry
12.4.6 Others
12.5 Middle East and Africa Cancer Tumor Profiling Market (2017-2032) by Application
12.5.1 Market Overview
12.5.2 Clinical
12.5.3 Research
12.6 Middle East and Africa Cancer Tumor Profiling Market (2017-2032) by Country
12.6.1 Saudi Arabia
12.6.2 United Arab Emirates
12.6.3 Nigeria
12.6.4 South Africa
12.6.5 Others
13 Regulatory Framework
13.1 Regulatory Overview
13.2 US FDA
13.3 EU EMA
13.4 INDIA CDSCO
13.5 JAPAN PMDA
13.6 Others
14 Patent Analysis
14.1 Analysis by Type of Patent
14.2 Analysis by Publication year
14.3 Analysis by Issuing Authority
14.4 Analysis by Patent Age
14.5 Analysis by CPC Analysis
14.6 Analysis by Patent Valuation
14.7 Analysis by Key Players
15 Strategic Initiatives
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership and Collaborations
15.3 Analysis by Joint Ventures
15.4 Analysis by Leading Players
15.5 Analysis by Geography
16 Supplier Landscape
16.1 Market Share Analysis, By Region (Top 5 Companies)
16.1.1 Market Share Analysis: Global
16.1.2 Market Share Analysis: North America
16.1.3 Market Share Analysis: Europe
16.1.4 Market Share Analysis: Asia-Pacific
16.1.5 Market Share Analysis: Others
16.2 Abbott Laboratories
16.2.1 Financial Analysis
16.2.2 Product Portfolio
16.2.3 Demographic Reach and Achievements
16.2.4 Mergers and Acquisitions
16.2.5 Certifications
16.3 Becton Dickinson and Company
16.3.1 Financial Analysis
16.3.2 Product Portfolio
16.3.3 Demographic Reach and Achievements
16.3.4 Mergers and Acquisitions
16.3.5 Certifications
16.4 Caris Life Sciences
16.4.1 Financial Analysis
16.4.2 Product Portfolio
16.4.3 Demographic Reach and Achievements
16.4.4 Mergers and Acquisitions
16.4.5 Certifications
16.5 Exact Sciences Corporation
16.5.1 Financial Analysis
16.5.2 Product Portfolio
16.5.3 Demographic Reach and Achievements
16.5.4 Mergers and Acquisitions
16.5.5 Certifications
16.6 F. Hoffmann-La Roche Ltd.
16.6.1 Financial Analysis
16.6.2 Product Portfolio
16.6.3 Demographic Reach and Achievements
16.6.4 Mergers and Acquisitions
16.6.5 Certifications
16.7 Hologic, Inc.
16.7.1 Financial Analysis
16.7.2 Product Portfolio
16.7.3 Demographic Reach and Achievements
16.7.4 Mergers and Acquisitions
16.7.5 Certifications
16.8 HTG Molecular Diagnostics Inc.
16.8.1 Financial Analysis
16.8.2 Product Portfolio
16.8.3 Demographic Reach and Achievements
16.8.4 Mergers and Acquisitions
16.8.5 Certifications
16.9 Illumina Inc.
16.9.1 Financial Analysis
16.9.2 Product Portfolio
16.9.3 Demographic Reach and Achievements
16.9.4 Mergers and Acquisitions
16.9.5 Certifications
16.10 Laboratory Corporation of America Holdings
16.10.1 Financial Analysis
16.10.2 Product Portfolio
16.10.3 Demographic Reach and Achievements
16.10.4 Mergers and Acquisitions
16.10.5 Certifications
16.11 NeoGenomics Laboratories
16.11.1 Financial Analysis
16.11.2 Product Portfolio
16.11.3 Demographic Reach and Achievements
16.11.4 Mergers and Acquisitions
16.11.5 Certifications
16.12 Qiagen N.V.
16.12.1 Financial Analysis
16.12.2 Product Portfolio
16.12.3 Demographic Reach and Achievements
16.12.4 Mergers and Acquisitions
16.12.5 Certifications
16.13 Siemens AG
16.13.1 Financial Analysis
16.13.2 Product Portfolio
16.13.3 Demographic Reach and Achievements
16.13.4 Mergers and Acquisitions
16.13.5 Certifications
16.14 Sysmex Corporation
16.14.1 Financial Analysis
16.14.2 Product Portfolio
16.14.3 Demographic Reach and Achievements
16.14.4 Mergers and Acquisitions
16.14.5 Certifications
16.15 GenScript
16.15.1 Financial Analysis
16.15.2 Product Portfolio
16.15.3 Demographic Reach and Achievements
16.15.4 Mergers and Acquisitions
16.15.5 Certifications
16.16 Guardant Health
16.16.1 Financial Analysis
16.16.2 Product Portfolio
16.16.3 Demographic Reach and Achievements
16.16.4 Mergers and Acquisitions
16.16.5 Certifications
17 Global Cancer Tumor Profiling Market – Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Purchase Options 10% off
Call us
Purchase Full Report
Datasheet
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER